{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:10:34Z","timestamp":1793261434383,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Medical Research Future Fund","award":["MRF1199853"],"award-info":[{"award-number":["MRF1199853"]}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1092957"],"award-info":[{"award-number":["APP1092957"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022885","name":"PKD Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022885","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001922","name":"Efficacy and Mechanism Evaluation Programme","doi-asserted-by":"publisher","award":["NIHR156614"],"award-info":[{"award-number":["NIHR156614"]}],"id":[{"id":"10.13039\/501100001922","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["23\/093\/A"],"award-info":[{"award-number":["23\/093\/A"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["IIRP-2023-4050"],"award-info":[{"award-number":["IIRP-2023-4050"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-025-09010-6","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T08:58:50Z","timestamp":1756112330000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Implementation of Metformin Therapy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD): study protocol for a phase III, multi-centre, randomized, placebo-controlled trial evaluating the long-term efficacy of metformin in slowing the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease"],"prefix":"10.1186","volume":"26","author":[{"given":"Kitty St","family":"Pierre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragada","family":"El-Damanawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel M.","family":"Hawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea K.","family":"Viecelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivekanand","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suetonia C.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreto","family":"Gesualdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charani","family":"Kiriwandeniya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pushparaj","family":"Velayudham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza A.","family":"Vergara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor","family":"Mihala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misa","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peta-Ann Paul","family":"Brent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8752-2551","authenticated-orcid":false,"given":"Andrew J.","family":"Mallett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"IMPEDE-PKD Global\u00a0Steering Committee\u00a0(see Appendix)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"issue":"2","key":"9010_CR1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.kint.2024.07.010","volume":"107","author":"VE Torres","year":"2025","unstructured":"Torres VE, et al. Kdigo 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary. Kidney Int. 2025;107(2):234\u201354.","journal-title":"Kidney Int"},{"issue":"2","key":"9010_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/ki.2009.128","volume":"76","author":"VE Torres","year":"2009","unstructured":"Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int. 2009;76(2):149\u201368.","journal-title":"Kidney Int"},{"issue":"25","key":"9010_CR3","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407\u201318.","journal-title":"N Engl J Med"},{"issue":"3","key":"9010_CR4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1042\/BJ20150497","volume":"471","author":"R Pryor","year":"2015","unstructured":"Pryor R, Cabreiro F. Repurposing metformin: an old drug with new tricks in its binding pockets. Biochem J. 2015;471(3):307\u201322.","journal-title":"Biochem J"},{"key":"9010_CR5","doi-asserted-by":"crossref","unstructured":"De\u00a0Broe, Marc\u00a0E., F. Kajbaf, and J.-D. Lalau, Renoprotective Effects of Metformin. Nephron, 2018;\u00a0138(4): p. 261\u2013274.","DOI":"10.1159\/000481951"},{"issue":"2","key":"9010_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1067\/mlc.2003.13","volume":"141","author":"M Sutter","year":"2003","unstructured":"Sutter M, Germino GG. Autosomal dominant polycystic kidney disease: Molecular genetics and pathophysiology. J Lab Clin Med. 2003;141(2):91\u2013101.","journal-title":"J Lab Clin Med"},{"issue":"4","key":"9010_CR7","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/jcp.25598","volume":"232","author":"S Ravindran","year":"2017","unstructured":"Ravindran S, et al. Nephroprotective Effects of Metformin in Diabetic Nephropathy: METFORMIN AND ITS NEPHROPROTECTIVE EFFECTS. J Cell Physiol. 2017;232(4):731\u201342.","journal-title":"J Cell Physiol"},{"issue":"9","key":"9010_CR8","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","volume":"60","author":"G Rena","year":"2017","unstructured":"Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577\u201385.","journal-title":"Diabetologia"},{"issue":"1","key":"9010_CR9","doi-asserted-by":"publisher","first-page":"F27","DOI":"10.1152\/ajprenal.00298.2021","volume":"322","author":"NM Pastor-Soler","year":"2022","unstructured":"Pastor-Soler NM, et al. Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model. Am J Physiol Renal Physiol. 2022;322(1):F27\u201341.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"11","key":"9010_CR10","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1007\/s13300-021-01155-2","volume":"12","author":"C Aiken","year":"2021","unstructured":"Aiken C, et al. An Update to the Article \u201cEfficacy and Side Effect Profile of Different Formulations of Metformin: A Systematic Review and Meta-Analysis.\u201d Diabetes Ther. 2021;12(11):2813\u20136.","journal-title":"Diabetes Ther"},{"issue":"2","key":"9010_CR11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2337\/dc11-1582","volume":"35","author":"L Reinstatler","year":"2012","unstructured":"Reinstatler L, et al. Association of Biochemical B12 Deficiency With Metformin Therapy and Vitamin B12 Supplements: The National Health and Nutrition Examination Survey, 1999\u20132006. Diabetes Care. 2012;35(2):327\u201333.","journal-title":"Diabetes Care"},{"key":"9010_CR12","doi-asserted-by":"crossref","unstructured":"Salpeter, S.R., et al., Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane library. 2010(4).","DOI":"10.1002\/14651858.CD002967.pub4"},{"issue":"1","key":"9010_CR13","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12882-019-1463-2","volume":"20","author":"BM Sorohan","year":"2019","unstructured":"Sorohan BM, et al. A single-arm pilot study of metformin in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2019;20(1):276.","journal-title":"BMC Nephrol"},{"key":"9010_CR14","doi-asserted-by":"publisher","DOI":"10.25259\/IJN_100_2024","author":"V Venkatasubramanian","year":"2024","unstructured":"Venkatasubramanian V, et al. Metformin versus standard of care in patients with autosomal dominant polycystic kidney disease \u2013 a randomized control trial. Indian J Nephrol. 2024. https:\/\/doi.org\/10.25259\/IJN_100_2024.","journal-title":"Indian J Nephrol"},{"issue":"7","key":"9010_CR15","first-page":"S242","volume":"4","author":"A Pasari","year":"2019","unstructured":"Pasari A, et al. SUN-200 role of metformin in ADPKD patients. Kidney Int. 2019;4(7):S242.","journal-title":"Kidney Int"},{"issue":"4","key":"9010_CR16","first-page":"S213","volume":"6","author":"A Roy Chaudhary","year":"2021","unstructured":"Roy Chaudhary A, et al. POS-494 an open label randomized controlled study to evaluate the role of Metformin to retard the progression of ADPKD. Kidney Int. 2021;6(4):S213\u20134.","journal-title":"Kidney Int"},{"issue":"3","key":"9010_CR17","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.kint.2021.06.013","volume":"100","author":"RD Perrone","year":"2021","unstructured":"Perrone RD, et al. Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD). Kidney Int. 2021;100(3):684\u201396.","journal-title":"Kidney Int"},{"key":"9010_CR18","doi-asserted-by":"crossref","unstructured":"Brosnahan, G.M., et al., Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study. Am J Kidney Dis, 2021.","DOI":"10.1053\/j.ajkd.2021.06.026"},{"issue":"8","key":"9010_CR19","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/nep.12658","volume":"21","author":"GK Rangan","year":"2016","unstructured":"Rangan GK, et al. KHA-cari guideline recommendations for the diagnosis and management of autosomal dominant polycystic kidney disease. Nephrology. 2016;21(8):705\u201316.","journal-title":"Nephrology"},{"issue":"4","key":"9010_CR20","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1185\/030079904125003278","volume":"20","author":"L Blonde","year":"2004","unstructured":"Blonde L, et al. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin. 2004;20(4):565\u201372.","journal-title":"Curr Med Res Opin"},{"key":"9010_CR21","unstructured":"Kidney Health Australia, Acute Kidney Injury Sick Day Plan factsheet. 2017."},{"issue":"24","key":"9010_CR22","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","volume":"371","author":"RW Schrier","year":"2014","unstructured":"Schrier RW, et al. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014;371(24):2255\u201366.","journal-title":"N Engl J Med"},{"issue":"6","key":"9010_CR23","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1073\/pnas.1011498108","volume":"108","author":"V Takiar","year":"2011","unstructured":"Takiar V, et al. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci U S A. 2011;108(6):2462\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"9010_CR24","doi-asserted-by":"publisher","first-page":"222","DOI":"10.5694\/mja11.11329","volume":"197","author":"DW Johnson","year":"2012","unstructured":"Johnson DW, et al. Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: new developments and revised recommendations. Med J Aust. 2012;197(4):222\u20133.","journal-title":"Med J Aust"},{"issue":"10","key":"9010_CR25","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336.","journal-title":"Qual Life Res"},{"key":"9010_CR26","unstructured":"Otsuka Pharmaceutical Developement & Commercialization Inc, Autosomal Dominant Polycystic Kidney Disease Pain and Discomfort Scale (ADPKD-PDS). 2016, Mapi Research Trust. ."},{"issue":"2","key":"9010_CR27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/BF01535722","volume":"33","author":"J Svedlund","year":"1988","unstructured":"Svedlund J, Sj\u00f6din I, Dotevall G. GSRS-A clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988;33(2):129\u201334.","journal-title":"Dig Dis Sci"},{"issue":"20","key":"9010_CR28","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377(20):1930\u201342.","journal-title":"N Engl J Med"},{"issue":"9","key":"9010_CR29","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1681\/ASN.2019010007","volume":"30","author":"LA Inker","year":"2019","unstructured":"Inker LA, et al. Gfr slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials. J Am Soc Nephrol. 2019;30(9):1735\u201345.","journal-title":"J Am Soc Nephrol"},{"key":"9010_CR30","unstructured":"Inc., O.P.D.C. Autosomal Dominant Polycystic Kidney Disease Pain and Discomfort Scale (ADPKD-PDS). 2016; Available from: https:\/\/eprovide.mapi-trust.org\/instruments\/autosomal-dominant-polycystic-kidney-disease-pain-and-discomfort-scale."},{"key":"9010_CR31","doi-asserted-by":"crossref","unstructured":"Expert Panel on Detection, E.T.o.H.B.C.i.A., Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 2001. 285(19): p. 2486\u20132497.","DOI":"10.1001\/jama.285.19.2486"},{"issue":"2","key":"9010_CR32","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, et al. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"key":"9010_CR33","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208\u2013103208.","journal-title":"J Biomed Inform"},{"issue":"may08 1","key":"9010_CR34","doi-asserted-by":"publisher","first-page":"h2147","DOI":"10.1136\/bmj.h2147","volume":"350","author":"K Loudon","year":"2015","unstructured":"Loudon K, et al. The precis-2 tool: designing trials that are fit for purpose. BMJ. 2015;350(may08 1):h2147\u2013h2147.","journal-title":"BMJ"},{"issue":"2","key":"9010_CR35","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1053\/j.ajkd.2020.05.024","volume":"77","author":"A Tong","year":"2021","unstructured":"Tong A, et al. Establishing a core outcome set for autosomal dominant polycystic kidney disease: report of the Standardized Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD) consensus workshop. Am J Kidney Dis. 2021;77(2):255\u201363.","journal-title":"Am J Kidney Dis"},{"key":"9010_CR36","unstructured":"U.S. National Library or Medicine. A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients (STAGED-PKD). Identifier: NCT03523728. 2021 23\/12\/21]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03523728."},{"key":"9010_CR37","unstructured":"U.S National Library of Medicine. A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON (FALCON). Identifier: NCT03918447. 2019 23\/12\/21]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03918447."},{"key":"9010_CR38","doi-asserted-by":"crossref","unstructured":"Rangan, G.K., et al., Prescribed Water Intake in Autosomal Dominant Polycystic Kidney Disease. N Engl J Med Evidence, 2021.","DOI":"10.1002\/9781119105954.ch19"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09010-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09010-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09010-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T05:51:12Z","timestamp":1757483472000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-09010-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9010"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09010-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"3 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval for the IMPEDE-PKD trial was obtained in Queensland, Australia, from Metro South Hospital and Health Service Human Research and Ethics Committee (approval reference HREC\/2021\/QMS\/70436). The study has received local governance approvals at each of the participating sites. Each participating jurisdiction will ensure relevant regulatory and ethical approvals are received prior to the trial beginning in that country.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Consent for publication is not applicable since there are no identifying images or other personal or clinical details of participants presented. A model participant information sheet and consent form are provided.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AJM has previously received research funding from Sanofi-Genzyme, been a member of a Medical Advisory Board for Otsuka Australia, and been clinical trial local site Principal Investigator for Reata, Sanofi-Genzyme and Dicerna. AJM is supported by a Queensland Government Advancing Clinical Research Fellowship. DWJ has received consultancy fees, research grants, speaker\u2019s honoraria and travel sponsorships from Baxter Healthcare and Fresenius Medical Care, consultancy fees from Astra Zeneca, Bayer and AWAK, speaker\u2019s honoraria from ONO and Boehringer Ingelheim & Lilly, and travel sponsorships from Ono and Amgen. VJ reports consulting fee\/honoraria from Bayer, Astra Zeneca, Boehringer Ingelheim, Biocryst, Vera, Visterra, Otsuka, Novartis, Astra Zeneca, Chinook, Biocryst and Alpine under the policy of all payments going to the organization. The other coauthors declare no relevant conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"302"}}